DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis: Implications for Surveillance

27Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

Abstract

Background: Stool DNA testing in patients with inflammatory bowel disease (IBD) may detect colorectal cancer and advanced precancers with high sensitivity; less is known about the presence of DNA markers in small IBD lesions, their association with metachronous neoplasia, or contribution to stool test positivity. Methods: At a single center in 2 blinded phases, we assayed methylated bone morphogenic protein 3, methylated N-Myc downstream-regulated gene 4, and mutant KRAS in DNA extracted from paraffin-embedded benign lesions, and matched control tissues of patients with IBD, who were followed for subsequent colorectal dysplasia. Stool samples from independent cases and controls with lesions <1 cm or advanced neoplasms were assayed for the same markers. Results: Among IBD lesions (29 low-grade dysplasia, 19 serrated epithelial change, and 10 sessile serrated adenoma/polyps), the prevalence of methylation was significantly higher than in mucosae from 44 matched IBD controls (P < 0.0001 for methylated bone morphogenic protein 3 or methylated N-Myc downstream-regulated gene 4). KRAS mutations were more abundant in serrated epithelial change than all other groups (P < 0.001). Subsequent dysplasia was not associated with DNA marker levels. In stools, the sensitivity of methylated bone morphogenic protein 3 as a single marker was 60% for all lesions <1 cm, 63% for low-grade dysplasia ≥1 cm and 81% for high-grade dysplasia/colorectal cancer, all at 91% specificity (P < 0.0001). Conclusions: Selected DNA markers known to be present in advanced IBD neoplasia can also be detected in both tissues and stools from IBD patients with small adenomas and serrated lesions. Mutant KRAS exfoliated from serrated epithelial change lesions might raise false-positive rates. These findings have relevance to potential future applications of stool DNA testing for IBD surveillance.

References Powered by Scopus

Multitarget stool DNA testing for colorectal-cancer screening

1322Citations
N/AReaders
Get full text

Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)

950Citations
N/AReaders
Get full text

Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies

732Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Colorectal Cancer in Inflammatory Bowel Disease

210Citations
N/AReaders
Get full text

Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer

86Citations
N/AReaders
Get full text

KRAS and TP53 mutations in inflammatory bowel diseaseassociated colorectal cancer: A meta-analysis

50Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Johnson, D. H., Taylor, W. R., Aboelsoud, M. M., Foote, P. H., Yab, T. C., Cao, X., … Kisiel, J. B. (2016). DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn’s Colitis: Implications for Surveillance. In Inflammatory Bowel Diseases (Vol. 22, pp. 1559–1567). Lippincott Williams and Wilkins. https://doi.org/10.1097/MIB.0000000000000795

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 22

63%

Researcher 7

20%

Lecturer / Post doc 4

11%

Professor / Associate Prof. 2

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 26

76%

Biochemistry, Genetics and Molecular Bi... 5

15%

Agricultural and Biological Sciences 2

6%

Computer Science 1

3%

Save time finding and organizing research with Mendeley

Sign up for free